Rein Therapeutics, Inc. received a notice of delisting from the Nasdaq Stock Market on August 21, 2026, due to failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive trading days under Rule 5550(a)(1). The company has an 180-day compliance period ending February 17, 2027, to restore the stock price above $1.00 for at least 10 consecutive business days. Failure to regain compliance may result in further suspension and delisting procedures. Rein Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026. Shareholders elected Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D. as Class III directors. Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 100 million to 200 million shares. Additionally, the meeting resulted in the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and the advisory approval of executive officer compensation. Rein Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.